As informed in Soft-Ox Solutions AS' notice release 13:45 today, the general
meeting approved inter alia the private placement and the debt conversion. A
minor adjustment with regard to issued shares and gross proceeds were resolved
by the general meeting:  
The general meeting resolved to issue 492,695,819 shares at a subscription price
of NOK 0.2 per share, raising NOK 98,539,167 in gross proceed in the private
placement and the debt conversion. 
The share capital of the Company will following the registration of the new
shares private placement and the debt conversion be NOK 10 068 473,38 divided on
503 423 609 shares with a nominal value of NOK 0.02 per share. 
Oslo 27 March 2024 
For any questions or interview requests, please contact: 
Geir Almås, Chair of SoftOx Solutions AS 
Mail: ir@soft-ox.com 
Phone: Geir Almås: (+47) 977 59 071 
About SoftOx Solutions AS 
SoftOx Solutions AS (SoftOx) is a Medtech and pharmaceutical company listed on
Euronext Growth Oslo under 'SOFTX'. SoftOx Solutions AS was founded in 2012 and
is headquartered in Oslo. The SoftOx Solutions Group includes: the holding
company SoftOx Solutions AS, the Malmö subsidiary, and subsidiaries SoftOx
Defense Solutions AS and SoftOx Disinfection AS. SoftOx is developing a highly
effective antimicrobial solution for use in biofilm, viral and antimicrobial
resistant infections. The patent-protected technology is based on extensive
research and development in partnership with leading Nordic research institutes.
For more information on SoftOx, visit www.soft-ox.com